Literature DB >> 15107804

Prostate cancer invasion is influenced more by expression of a CD44 isoform including variant 9 than by Muc18.

Archangel Levi Omara-Opyene1, Jingxin Qiu, Girish V Shah, Kenneth A Iczkowski.   

Abstract

The standard form of cell adhesion glycoprotein CD44 is a metastasis suppressor in prostate cancer. However, we previously showed by RT-PCR and Western blotting that cancer overexpresses unique CD44 variant v7-v10 isoforms. Muc18 is another cell adhesion marker reportedly overexpressed by prostate cancer. Matched frozen section-confirmed tumor and benign tissues were harvested from 10 prostatectomy specimens and tumor was microdissected from two lymph node metastases. Tissues were homogenized for RNA preparations, and RT-PCR was performed for the CD44v7-v10 sequence. In cultured prostate cancer cells, we caused RNA interference against CD44v9 and/or Muc18. We used PC3M cells and a derivative cell line called G(s)alpha, that constitutively expresses this G-protein and is more invasive. Lipofection was performed for a green fluorescent protein plasmid and for two 22-mer DNA fragments, cloned into a plasmid expression vector to generate hairpin, interfering dsRNA. Assays for invasion into Matrigel, a basement membrane matrix, were performed in 4-5 experiments. RT-PCR demonstrated expression of a 608 bp band representing CD44v7-v10 or a 638 bp band of CD44v6-v10 in prostate cancer tissues and metastases but not benign tissue. Cultured G(s)alpha cells overexpressed CD44v9 by comparison with PC3M cells. At 90 h after 6-hour lipofection, protein silencing was evident by Western blots. Silencing the CD44v9 expression reduced invasiveness into Matrigel to 21.6+/-7.0% in PC3M cells (P<0.001) and 31.2+/-18.3% in G(s)alpha cells (P=0.001), compared to cells exposed to transfection vehicle alone. Silencing Muc18 expression reduced invasiveness to 76.9+/-13.5% of the control value in PC3M cells (P<0.05) and 84.8+/-29.9% in G(s)alpha cells (P=0.18). Prostate cancer invasion is facilitated more by its overexpression of CD44 variant 9 than by Muc18. Its relative overexpression by G(s)alpha cells is a novel finding, suggesting a link between signal transduction and cell adhesion marker expression.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15107804     DOI: 10.1038/labinvest.3700112

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  25 in total

1.  CD44 is a biomarker associated with human prostate cancer radiation sensitivity.

Authors:  WeiWei Xiao; Peter H Graham; Carl A Power; Jingli Hao; John H Kearsley; Yong Li
Journal:  Clin Exp Metastasis       Date:  2011-09-28       Impact factor: 5.150

Review 2.  The androgen receptor and stem cell pathways in prostate and bladder cancers (review).

Authors:  Katarzyna Marcinkiewicz; Kymora B Scotland; Stephen A Boorjian; Emeli M Nilsson; Jenny Liao Persson; Per Anders Abrahamsson; Cinzia Allegrucci; Ieuan A Hughes; Lorraine J Gudas; Nigel P Mongan
Journal:  Int J Oncol       Date:  2011-09-28       Impact factor: 5.650

3.  Stromal hyaluronan interaction with epithelial CD44 variants promotes prostate cancer invasiveness by augmenting expression and function of hepatocyte growth factor and androgen receptor.

Authors:  Shibnath Ghatak; Vincent C Hascall; Roger R Markwald; Suniti Misra
Journal:  J Biol Chem       Date:  2010-03-03       Impact factor: 5.157

4.  Phenyl-methylene hydantoins alter CD44-specific ligand binding of benign and malignant prostate cells and suppress CD44 isoform expression.

Authors:  Kui Yang; Yaqiong Tang; Kenneth A Iczkowski
Journal:  Am J Transl Res       Date:  2010-01-01       Impact factor: 4.060

5.  Cell adhesion molecule CD44: its functional roles in prostate cancer.

Authors:  Kenneth A Iczkowski
Journal:  Am J Transl Res       Date:  2010-09-12       Impact factor: 4.060

6.  The role of mediators of cell invasiveness, motility, and migration in the pathogenesis of silent corticotroph adenomas.

Authors:  Ozgur Mete; Caroline Hayhurst; Hussein Alahmadi; Eric Monsalves; Hasan Gucer; Fred Gentili; Shereen Ezzat; Sylvia L Asa; Gelareh Zadeh
Journal:  Endocr Pathol       Date:  2013-12       Impact factor: 3.943

7.  Silibinin suppresses CD44 expression in prostate cancer cells.

Authors:  Alina M Handorean; Kui Yang; Eric W Robbins; Thomas W Flaig; Kenneth A Iczkowski
Journal:  Am J Transl Res       Date:  2009-01-01       Impact factor: 4.060

8.  Invasive prostate cancer cells are tumor initiating cells that have a stem cell-like genomic signature.

Authors:  George J Klarmann; Elaine M Hurt; Lesley A Mathews; Xiaohu Zhang; Maria A Duhagon; Tashan Mistree; Suneetha B Thomas; William L Farrar
Journal:  Clin Exp Metastasis       Date:  2009-02-17       Impact factor: 5.150

9.  Persistent exposure to Mycoplasma induces malignant transformation of human prostate cells.

Authors:  Kazunori Namiki; Steve Goodison; Stacy Porvasnik; Robert W Allan; Kenneth A Iczkowski; Cydney Urbanek; Leticia Reyes; Noboru Sakamoto; Charles J Rosser
Journal:  PLoS One       Date:  2009-09-01       Impact factor: 3.240

10.  Stable alterations of CD44 isoform expression in prostate cancer cells decrease invasion and growth and alter ligand binding and chemosensitivity.

Authors:  Kui Yang; Yaqiong Tang; Gabriel K Habermehl; Kenneth A Iczkowski
Journal:  BMC Cancer       Date:  2010-01-14       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.